Relapsing multiple sclerosis (RMS) is the most common form of multiple sclerosis, characterized by episodes of new or worsening neurological symptoms. According to the World Health Organization, over 1.8 million people are affected by MS globally. Relapsing multiple sclerosis pipeline analysis by Expert Market Research highlights significant advancements in small molecules, biologics, and gene therapies. The growing focus on targeted therapies, immunomodulators, and monoclonal antibodies is driving innovation in the relapsing multiple sclerosis pipeline. Moreover, with increased R&D investments, the clinical pipeline for relapsing multiple sclerosis is expected to grow steadily in the coming years.
Major companies involved in the relapsing multiple sclerosis pipeline analysis include Novartis Pharmaceuticals, Bristol-Myers Squibb, and others.
Leading drugs currently in the pipeline include BMS-986374, Fenebrutinib, and others.
Advancements in B-cell targeted monoclonal antibodies, novel oral small molecules, and increased clinical focus on remyelination and neuroprotection strategies are driving the growth of the relapsing multiple sclerosis pipeline.
The Relapsing Multiple Sclerosis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into relapsing multiple sclerosis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for relapsing multiple sclerosis. The relapsing multiple sclerosis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The relapsing multiple sclerosis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with relapsing multiple sclerosis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to relapsing multiple sclerosis.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Relapsing multiple sclerosis (RMS) is a chronic autoimmune disorder where the immune system attacks the protective myelin sheath covering nerve fibers in the central nervous system. This leads to inflammation and nerve damage, causing symptoms such as vision problems, muscle weakness, and cognitive impairment. RMS is characterized by flare-ups (relapses) followed by periods of partial or complete recovery (remissions).
Relapsing multiple sclerosis treatments aim to reduce relapses, delay disability progression, and control inflammation. These include disease-modifying therapies, monoclonal antibodies, oral agents, and injectable medications. In September 2024, the U.S. FDA approved Ocrevus Zunovo, the first and only twice-yearly, 10-minute subcutaneous injection for RMS. It offers flexible access without IV infrastructure, supported by ten years of efficacy data.
Relapsing forms of multiple sclerosis (MS), especially relapsing-remitting MS (RRMS), involve recurrent episodes of neurological symptoms followed by recovery. According to a study published in 2025, an estimated 1.89 million people were living with MS globally in 2021, with a prevalence of 23.9 cases per 100,000 population. It is estimated that over 16,000 deaths are due to MS annually, with the highest burden in North America and Western Europe. The incidences are projected to increase by 2050.
This section of the report covers the analysis of relapsing multiple sclerosis drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III, with 59.26%, covers a major share of the total relapsing multiple sclerosis clinical trials. Phase II follows at 40.74%, and Phase IV holds at 25.93%. Phase I contributes 22.22%, and Early Phase I represents 4.88%. This ensures steady growth and therapeutic advancement in the relapsing multiple sclerosis pipeline.
The drug molecule categories covered under the relapsing multiple sclerosis pipeline analysis include monoclonal antibodies, small molecules, recombinant fusion proteins, peptides, gene therapies, and others. The relapsing multiple sclerosis report provides a comparative analysis of the drug classes for each candidate in various phases of clinical trials for relapsing multiple sclerosis.
Bruton’s tyrosine kinase (BTK) inhibitors are emerging as a novel class in the relapsing multiple sclerosis drug pipeline. For instance, Roche’s investigational therapy, fenebrutinib, showed near-complete suppression of disease activity and no disability progression over 48 weeks in Phase II trial. It also demonstrated significant MRI lesion reduction, with a favorable safety profile consistent across multiple indications.
The EMR report for the relapsing multiple sclerosis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed relapsing multiple sclerosis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in relapsing multiple sclerosis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for relapsing multiple sclerosis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of relapsing multiple sclerosis drug candidates.
BMS-986374 (ozanimod), sponsored by Bristol-Myers Squibb, is currently being evaluated in a Phase IV study to determine its effectiveness and safety in Chinese adults with relapsing multiple sclerosis. This study is assessing the therapeutic impact of Zeposia, an oral S1P receptor modulator that selectively binds to S1P1 and S1P5, preventing lymphocyte migration from lymph nodes and potentially reducing inflammatory damage in the central nervous system.
Fenebrutinib is being evaluated in a Phase III study sponsored by Hoffmann-La Roche to compare its efficacy and safety against teriflunomide in adults with relapsing multiple sclerosis. The study aims to assess disability progression and relapse rates. Fenebrutinib is a highly selective, reversible oral BTK inhibitor, designed to modulate B-cell activity and innate immune responses with minimal off-target effects.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Relapsing Multiple Sclerosis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for relapsing multiple sclerosis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into relapsing multiple sclerosis collaborations, regulatory environments, and potential growth opportunities.
Relapsing Remitting Multiple Sclerosis Drug Pipeline Analysis Report
Global Multiple Sclerosis Treatment Market Report and Forecast
Upto 25% Off
USD
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share